BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:
A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. The webcast will be archived on OraSure’s website and will be available for approximately 90 days.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
| Investor Contact: Jason Plagman VP, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: Amy Koch Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.64 |
| Daily Change: | -0.15 -3.96 |
| Daily Volume: | 2,095,289 |
| Market Cap: | US$271.510M |
December 19, 2024 November 06, 2024 August 06, 2024 February 27, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
